Latest Security News

Chimeric Therapeutics has raised $8.4 million to fully fund its lead CHM CDH17 CAR-T Phase 1/2 trial through Phase 1, while initiating a strategic reset to sharpen focus and reduce costs.

Metgasco has pushed back the deadline for Vintage Energy’s commitment to acquire its stake in the Odin and Vali Gas Fields, extending the timeline while keeping the overall transaction completion date intact.

Carnegie Clean Energy’s Spanish subsidiary has sold its 2025 Basque R&D tax deductions for €773,163, securing immediate funding to advance its ocean wave energy technology under the ACHIEVE Programme.

Neurizon Therapeutics has launched a A$24.2 million equity raise to fund the next phase of clinical trials for its lead drug NUZ-001 targeting ALS, supported by a global licensing deal and a flexible convertible note facility.

Neurizon Therapeutics has locked in a $44 million funding package to fully support its lead drug NUZ-001 in the HEALEY ALS Platform Trial, marking a critical step toward potential regulatory approval and broader neurodegenerative applications.

MRG Metals has raised $0.73 million through a placement to advance its rare earth and heavy mineral sands projects in Mozambique and South Africa, including a strategic acquisition and mining license progression.

MRG Metals has completed the acquisition of the Garies Rare Earth Project, a high-grade, magnet-rich rare earth asset in South Africa, significantly boosting its critical minerals portfolio. The deal positions MRG for rapid development with a clear pathway to early cashflow and complements its existing projects in Mozambique and the Adriano–Fotinho corridor.

OZZ Resources has entered a binding option agreement with Scorpion Minerals, offering an exclusive chance to acquire its key tenements for $2.6 million plus a gold production royalty. The deal awaits shareholder approval and hinges on several regulatory and operational conditions.

BCI Minerals has secured crucial environmental approvals to proceed with its optimized dredging strategy at the Mardie Salt Operation, setting the stage for first salt shipments by late 2026.

Invion Limited’s partner Hanlim Pharm, backed by South Korea’s government grant, has secured up to A$2 million in non-dilutive funding to advance preclinical studies of HL270 for oesophageal cancer, paving the way for human trials in Australia.

Artrya Limited has signed a significant five-year commercial agreement with Cone Health, marking its third U.S. customer and solidifying its foothold in the American healthcare market with its AI-powered Salix platform.

Rox Resources has completed a $200 million capital raise, including a $134 million second tranche placement, to fund development of its Youanmi Gold Project in Western Australia.